As a primary brain tumor of the highest morbidity and mortality that mainly occurs among the elderly over 50 years old, Glioblastoma (GBM) has high heterogeneity and resistance to radiotherapy and chemotherapy, and the median survival period after treatment is only 15 months. An important reason f...
et al. Complications after combination of chemotherapy and radiation for malignant brain tumours. Acta neurochir 65, 167–173 (1982). https://doi.org/10.1007/BF01405842 Download citation Issue DateSeptember 1982 DOIhttps://doi.org/10.1007/BF01405842 Keywords Public Health Radiation Survival Rate ...
Survival rates among patients diagnosed with primary malignant brain tumors vary inversely with age. For example, among patients between the ages of 45 and 54, the 5-year survival rate is 24%, while this rate is only 5% for patients who are at least 75 years old (Table 87.1) [1]. In...
Among them, glioblastoma multiform (GBM) is the most common malignant primary brain tumor in adults with a poor prognosis of 5-year survival rate less than 5% following the standard therapy. In the past 17 years, the standard therapy of GBM has been surgery followed by radiation and the ...
Malignant rhabdoid tumor of the kidney occurs most commonly in infants (mean age, 16.8 months), and preponderantly in males. This tumor is associated with an 80% mortality rate and can metastasize to liver, lung, brain, bone, and soft tissues.3 It is associated with central nervous system...
Glioblastoma is the most common malignant primary brain tumor with high relapse rates, mortality and poor prognosis1,2. Median survival of glioblastoma patients is <15 months even after individualized therapies3,4. The standard approach to managing glioblastoma is maximal surgery followed by radiotherapy...
Although melanoma accounts for only approximately 4% of all skin cancers it is responsible for more than 73% of skin cancer deaths.2Once melanoma has metastasized to the lymph nodes (Stage III), the 5-year survival rate following surgical removal is only 20 to ...
North American Brain Tumor Consortium, Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol 2008;10 (2) 162- 170PubMedGoogle ScholarCrossref 21. Desjardins AReardon DAHerndon JE II et al. Bevacizumab plus irinotecan in recurrent ...
Compared to GBM, the genetic alteration ofPIK3CA(2%) andPIK3R1(0.3%) in medulloblastoma (MBM, Table1), which is the most aggressive malignant brain tumor that highly occurs in children and survival rate can reach 70% after active treatment, are less frequently observed [34]. However, enhance...
Glioblastoma (GBM) is the most common malignant primary brain tumor. Despite comprehensive treatment with traditional surgery, radiotherapy, and chemotherapy, the median survival rate is <14.6% and the 5-year survival rate is only 5%. FBXO22, a substrate receptor of the SCF ubiquitin ligases, ha...